The Time Toxicity of Cancer Treatment

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness

The ESCAPE Investigators and ESCAPE Study Coordinators* (2005) · JAMA · doi:10.1001/jama.294.13.1625 · Cited by 1,544

Balanced Crystalloids versus Saline in Noncritically Ill Adults

Self, W. H., Semler, M. W., Wanderer, J. P., Wang, L., Byrne, D. W., Collins, S. P., Slovis, C. M., Lindsell, C. J., Ehrenfeld, J. M., Siew, E. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711586 · Cited by 1,170

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Lamarca, Á., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S. J., Gillmore, R., Wadsley, J., Patel, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00027-9 · Cited by 781

NXY-059 for Acute Ischemic Stroke

Lees, K. R., Zivin, J. A., Ashwood, T., Davalos, A., Davis, S. M., Diener, H.-C., Grotta, J., Lyden, P., Shuaib, A., Hårdemark, H.-G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052980 · Cited by 660

Physical rehabilitation for older patients hospitalized for heart failure

Kitzman, D. W., Whellan, D. J., Duncan, P., Pastva, A. M., Mentz, R. J., Reeves, G. R., Nelson, M. B., Chen, H., Upadhya, B., Reed, S. D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026141 · Cited by 594

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309

Days Spent at Home — A Patient-Centered Goal and Outcome

Groff, A. C., Colla, C. H., & Lee, T. H.-Y. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1607206 · Cited by 272

Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings

Wierzbicki, M., Bowden, S. G., Robert, S. M., Wang, S., Toth, A. J., Imber, B. S., Pike, L., Tabar, V., Groeger, J. S., & Moss, N. S. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05626-z

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Ashbrook, C. Q., Gupta, V., Clark, N., Rings, V., Corona, L. E., Clayton, D. B., & Benedetti, D. J. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70404

Breaking Barriers in Obesity Care — Scaling a Primary Care Weight Management Program Statewide

Ro, S., McCauley, J., Schaeffer, J., Gupta, S., & Fiscus, L. C. (2026) · NEJM Catalyst · doi:10.1056/cat.25.0345

The Impact of Treatment Time Toxicity on Regimen Selection in Multiple Myeloma: A Single-Center Retrospective Study

Hachiya, K., Nishimura, K., Suzuki, K., Sekine, T., Masuya, M., & Tawara, I. (2026) · Internal Medicine · doi:10.2169/internalmedicine.7182-26

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial

Johnson, J. S., Miller, J. W., Hatoum, F., Schell, M. J., Yu, X., Souza, G. R., Mizelle, S. R., Gullapalli, K., Fazili, A. N., Jain, R., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73336-1

Cancer patients’ experiences of “time toxicity”: a qualitative meta-synthesis

Li, Z., Liu, Y., Zhang, J., Duan, J., Xiu, W., Zhang, W., Zhang, L., & Yang, H. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10828-2

Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?

Figen, M., Bölükbaş, M. K., Soydemir, G. P., & Üzel, E. K. (2026) · BMC Cancer · doi:10.1186/s12885-026-16295-6

Perspectives of Rectal Cancer Patients Undergoing Non-Operative Management (NOM): A Qualitative Study

Alam, A., Farooq, A., Udwadia, F. R., Raval, M. J., Karimuddin, A. A., Phang, P. T., Ghuman, A., & Brown, C. J. (2026) · Current Oncology · doi:10.3390/curroncol33060348

Chrónos and Káiros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments

Alberts, I., Sachpekidis, C., & Buchman, S. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07954-8

Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals

Forrest, R., Aggarwal, A. K., Tregear, M., Wynne, M., Lynch, H. F., Wagner, A. K., Jackson, E., & Naci, H. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.17450

Toward Home Cancer Care—Reducing Time Toxicity for the Right Patients With Prostate Cancer

Nguyen, D.-D., & Jacobs, B. L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.17474

Paid Sick Leave, Care Delays, and Mortality Risk in Working Cancer Survivors

Kohut-Jackson, A., Chino, F. L., Zheng, Z., Han, X., Johnson, K. J., Yabroff, K. R., Johnston, K. J., & Barnes, J. M. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00261

Measuring and quantifying treatment burden in individuals living with and beyond cancer: a scoping review

Duncan, L., Dixon, D. L., Allan, J., & Adam, R. (2026) · European Journal of Cancer Care · doi:10.48130/ejcc-0026-0001

Financial Toxicity of Shorter Versus Longer Partial Breast Irradiation: A Randomized Clinical Trial

Smith, G. L., Wu, C.-F., Joyner, M. M., Schlembach, P. J., Bloom, E. S., Reed, V. K., Graybill, J., Anderson, C., Lin, R., Dragun, A. E., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.05.046

Healthcare contact days in cancer survivors relative to those with no cancer history

Parsons, H. M., Newton, C. C., Gupta, A., Flanders, W. D., Patel, A. V., Bodelón, C., Zhong, C., Westmaas, J. L., & Rees‐Punia, E. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10884-8

A Multicentre Phase II Study of Trifluridine/Tipiracil in Recurrent/Metastatic Platinum-Resistant Nasopharyngeal Carcinomas

Low, J. L., Chong, W. Q., Hui, E. P., Tan, T. Z., Lai, W., Le, T. B. U., Sooi, K. W. X., Walsh, R. J., Li, W. Y., Kong, L. R., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-1167

First-line osimertinib in advanced EGFR-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohort

Suay, G., Esteban, S. C., Capdevila, P., García-Márquez, A., Garde, J., Espinosa-Olarte, P., Rondan, M. A., Contreras, S. S., Aparisi, F., Escoín, C., et al. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2026.100725

Patient, care partner, and oncologist perspectives on clinically important survival thresholds after considering time toxicity in advanced cancer

Gupta, A., Lin, K., Jansen, R. J., Stevens, S. X., George, M., Breininger, A., Booth, C. M., Parsons, H. M., Ziegenfuss, J. Y., Vogel, R. I., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag246

The experience of time toxicity in cancer patients: a meta-synthesis of qualitative research

Shi, Y., Wang, P., Ji, J., Zhao, X. L., & Wang, X. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10979-2

From matching to facilitation: Reframing AI’s role in clinical trial enrollment

Yaacov, A., Levi, E., & Peled, N. (2026) · Patterns · doi:10.1016/j.patter.2026.101591

Periodic surveillance of intraductal papillary mucinous neoplasms: gaps in evidence and future directions

Hamada, T., Oyama, H., Nakai, Y., & Petrov, M. S. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag225

Cancer Immunotherapy Stewardship — Cost-Neutral, Patient-Centered Dosing to Increase Infusion Center Efficiency

Moeller, J. A., Gyori, D. J., Gau, I., & Strohbehn, G. W. (2026) · NEJM Catalyst · doi:10.1056/cat.25.0416

The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence

Zeidan, A. M., Zhao, R., Christensen, D., Amin, J., & LeBlanc, T. W. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2705531

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe Upscaled: Protocol of a Pragmatic Cluster Randomized Trial of Enhanced Telehealth for Patients with Breast and Prostate Cancer (Preprint)Preprint

Bange, E. M., Malling, C. D., Reiner, A. S., Baser, R. E., Marcinkowski, K., Sadowsky, H., Wong, S., Lee-Teh, M., Traina, T. A., Sanford, R. A., et al. (2026) · doi:10.2196/preprints.107800

Workflow and dosimetric results for direct-to-unit single-fraction adaptive lung SBRT delivered on the ONE-STOP prospective pilot clinical trial

Forghani, F., Mazur, T. R., Schiff, J. P., Hong, D., D'Souza, A., Mueller, R., Hamilton, J., Harris, J., Jamruk, T., Hilliard, J., et al. (2026) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2026.101249

Healthcare burden in spina bifida: Measuring time toxicity in the first year of life

Ashbrook, C. Q., Pasala, R. R., Do, C. B., Rings, V., Corona, L. E., Frainey, B. T., & Clayton, D. B. (2026) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2026.106189

Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era

Hofmeister, E. N., & Major, A. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00786-1

Social determinants and equity across the gastric cancer continuum in Vietnam: a narrative review

Dong, H. D., Tran, T. N., & Giang, N. V. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04545-9

A 'Systematised-Review' and Meta-Analysis of The Anti-Cancer Therapeutic Potential of Nigella sativa (Black cumin) to Reduce Cancer Cell Proliferation and Induce Apoptosis within an In-vitro Framework.Preprint

Hussein, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-10620086/v1

A patient journey map study on time toxicity among young and middle-aged patients with breast cancer

Cui, L., Guan, Y., Chen, X., Sun, F., Wu, H., & Wang, Y. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1883712

Exploring patient perspectives of exercise in advanced pancreatic cancer care in Canada: A qualitative interpretive description

Cyr, C., Perry, B., Ramjeesingh, R., Blanchard, C., & Keats, M. R. (2026) · Palliative & Supportive Care · doi:10.1017/s1478951526103356

Characterizing Time Toxicity in Lung Cancer Clinical Trials: Development and Application of a Novel Time Burden Metric

Herrmann, A., Jain, S., Madlensky, L., & Bazhenova, L. A. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00295

A 'Systematised-Review' and Meta-Analysis of The Anti-Cancer Therapeutic Potential of Nigella sativa (Black cumin) to Reduce Cancer Cell Proliferation and Induce Apoptosis within an In-vitro Framework.Preprint

Hussein, Z. (2026) · Research Square · doi:10.21203/rs.3.rs-10620086/v2

Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab‐Paclitaxel as First‐Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic Cancer

Ikezawa, K., Imai, T., Takada, R., Yamai, T., Fukutake, N., Urabe, M., Kai, Y., Mukai, K., Nakabori, T., & Ohkawa, K. (2026) · Cancer Reports · doi:10.1002/cnr2.70691

Characterizing the Objective Time Spent on Health Care Activities in Clinic and at Home for Patients With Cancer

Rocque, G. B., Henderson, N. L., Parsons, H. M., Brown, K. A., Huang, Z., Gupta, A., Teoh, D. G. K., Fan, Y., Blaes, A. H., Dionne-Odom, J. N., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72277

Drivers of Change in Radiotherapy Practice: Lessons From a UK Tertiary Cancer Centre (2013–2023)

Kapadi, A., Price, G. J., Finn, C. F., Holley, R., Banfill, K., Walls, G., Marchant, T., Radhakrishna, G., Price, J., Choudhary, A., et al. (2026) · Clinical Oncology · doi:10.1016/j.clon.2026.104342

Nursing-related time toxicity: An evolutionary concept analysis

Wang, X., Cao, H., Hu, Y., & Fang, Q. (2026) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2026.105699

Real-World Clinical, Enviro-Logistical and Economic Implications of Sentinel Lymph Node Biopsy Omission in Early Breast Cancer

Lukac, S., Schäffler, H., Leinert, E., Reimer, T., Guthke, M., Blum, J., Nedoklan, M., Ebner, F. K., Dayan, D., Pfister, K., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20545-z

Experiences and perceived determinants of healthcare-related time toxicity among women with gestational diabetes mellitus: a qualitative study

Liu, J. B., Xu, W., Ma, J., Shang, X., Jia, M., & You, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1947845

Time toxicity in cancer care: a systematic review of definitions and measurement methods

Wee, I. J. Y., Min, C. H., Ling, S. S., Eu, E. W., Ying, T. S., Huat, I. T. B., & Yang, G. M. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11283-9

Neighborhood material deprivation and days at home after glioblastoma diagnosis

Saini, J., Lozano, C. S., Karthikeyan, V., Shakil, H., Malhotra, A. K., He, Y., Sykes, J., Lim-Fat, M. J., Badhiwala, J. H., Wilson, J. R., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05843-6

Time toxicity among patients with cancer: a scoping review

Liu, H., Ju, M., Wu, C., & Guo, L. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11308-3

Development and Validation of a Tool to Measure Documented Health Care Encounter Time

Chow, R., Bayrakdarian, S., Gojsevic, O., MacMillan, E., Balboni, T. A., Bowen, J., Bruera, E. D., Chan, R. J., Gupta, A., Hart, N. H., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.38034

Time Is Money, but for Whom? The Commodification of Time Toxicity in Oncology

Gupta, A., Patel, V. R., Sedhom, R., & Booth, C. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01458

The Hidden Harm of Administrative Toxicity

Berthaud, F. M., & Cheung, C. K. (2026) · Oncology Issues · doi:10.3928/25731777-20260601-03

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies

Mabuchi, S., Kusakabe, A., & Takimoto, Y. (2026) · Current Oncology · doi:10.3390/curroncol33100622

A prospective study evaluating the impact of waiting time on blood testing and clinical workflows in cancer patients

Sunakawa, Y., Arai, H., Kubota, Y., Nagata, Y., Takeda, H., Umemoto, K., Horie, Y., Izawa, N., Ogura, T., Okazuka, K., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03197-7

Frequency of Bloodwork in Patients on Immune Checkpoint Inhibitors

Goffin, J. R., Chan, S. W. S., & Pond, G. R. (2026) · Current Oncology · doi:10.3390/curroncol33100630

Minimal‐Burden Prosthodontics: Simple Care and Comprehensive Risk Assessment in Older Adults

Molinero‐Mourelle, P., Schimmel, M., & Mosaddad, S. A. (2026) · Gerodontology · doi:10.1111/ger.70132

Days at Home After Gastrointestinal Cancer Surgery as a Patient-Centered Outcome

Ribeiro, T., Bondzi‐Simpson, A., Chan, W. C., Mahar, A. L., Jerath, A., Coburn, N. G., & Hallet, J. I. (2026) · JAMA Surgery · doi:10.1001/jamasurg.2026.4890

Real-world analysis of infusion-related reactions in patients receiving subcutaneous daratumumab in Nova Scotia, Canada

Jang, H. W. (., Godin, J., Rolle, M., Torre, A. D. L., White, D. J., & Minard, L. V. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261500471

Crimes against Humanity in Breast Cancer

Bretz, P. (2026) · Journal of Surgery and Surgical Procedures · doi:10.47485/3069-8154.1038

Frailty and home time loss after surgical resection for patients with non-metastatic pancreatic cancer

Raymond-King, L., McGrath, S., Mukherjee, B., Parikh, H., Rothen, J., Dinan, M. A., Soulos, P. R., Gross, C. P., Festa, N., & Kunstman, J. W. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.104663

Administrative Workload and Associated Distress in Individuals Undergoing Cancer Therapy

Boyle, S. J., Parsons, H. M., Kyle, M. A., Jewett, P. I., Yang, G., Huang, Z., Gupta, A., Teoh, D. G. K., Fan, Y., Blaes, A. H., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72416

Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer

Quinn, P. L., Schaefer, M. L., & Ejaz, A. M. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00413

Pharmacist-led redesign of chemotherapy delivery and supportive care: effects on infusion capacity, aseptic workload, costs and resource stewardship in oncology practice

Dudík, B., Mriňáková, B., Kimliková, K., Waczulı́ková, I., Krajčík, O., Kilianova, Z., Blažová, N., Kosírová, S., Usakova, V., Gočárová, K., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1908515

The Toxicity of Time

Daily, K. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7907 · Cited by 19

Time Toxicity of Cancer Care—A Call to Action

Doshi, S. D., Rappaport, J. A., & Bange, E. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.47930 · Cited by 8

Time Is Money, but for Whom? The Commodification of Time Toxicity in Oncology

Gupta, A., Patel, V. R., Sedhom, R., & Booth, C. M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01458

‘Time Toxicity’ in the Metastatic Setting

DiGirolamo, E. (2026) · Oncology Times · doi:10.1097/01.cot.0000000000000380

Love in the Time of Cancer

Einhorn, L. H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9755 · Cited by 1